[Clinical effect of long-term administration of PSK in a combination in patients with malignant urologic cancer].
Long-term administration of PSK was made in 40 patients with urological cancer. Mean duration of the administration was 201, 358 and 243 days for the patients with bladder cancer, renal cancer and other urological cancers, respectively. The clinical evaluations were performed by the standard of Japan Society for Cancer Therapy and historical control study. In some cases, it seemed that the immunological therapy by PSK was a benefit to some degree. However, more accurate evaluation should be made by the matched control study.
D000230:Adenocarcinoma / Q000628:therapy; D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000368:Aged; D002295:Carcinoma, Transitional Cell / Q000628:therapy; D004407:Dysgerminoma / Q000628:therapy; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011509:Proteoglycans / Q000008:administration & dosage*; D013736:Testicular Neoplasms / Q000628:therapy; D014516:Ureteral Neoplasms / Q000628:therapy; D001749:Urinary Bladder Neoplasms / Q000628:therapy; D014571:Urologic Neoplasms / Q000628:therapy*
D000276:Adjuvants, Immunologic; D011509:Proteoglycans; C010770:polysaccharide-K